On May 1st, ICER released the results of its initial analyses to inform public debate of pricing for remdesivir (Gilead Sciences) and other future treatments of COVID-19. Working with external academic partners, ICER has developed ICER-COVID models comprising two alternative pricing paradigms for COVID-19 treatments: 1) “cost recovery” for the manufacturer, representing an estimate based on peer-reviewed methods of calculating the minimum costs of production for a course of therapy; and 2) traditional cost-effectiveness analyses looking at the incremental health benefits and costs within the health system. The models will be used to track and evaluate any potential future treatments for COVID-19. Click here to learn more about ICER’s adapted methods for assessing pricing during a pandemic.

Details on subsequent updates to the ICER-COVID models will be listed here.

For questions, please contact Meaghan Cummings at .

Associated Meetings

Key Dates

Associated Materials


05/01/2020 – 06/24/2020


06/24/2020 – 11/10/2020